The clinic has not been rated by the Better Business Bureau (BBB)
Key Takeaways Cagrisema 12mg combines 6mg cagrilintide (amylin agonist) and 6mg semaglutide (GLP-1 agonist) in a pre-filled, dial-a-dose pen for non-clinical research The dual-agonist mechanism produced 14.2% mean body-weight reduction at 68 weeks in type 2 diabetes trials, versus 10.2% for semaglutide alone Pre-filled format eliminates reconstitution error and maintains a fixed 1:1 peptide ratio across all injections Supplied with batch-specific Certificate of Analysis, EU GMP documentation, and full traceability for research compliance Not MHRA-authorised
Jakafi [package insert]
What they found: Melanotan II is 100 to 1000 more potent than native -MSH in melanocyte assays Cyclization preserves the active conformation longer than linear -MSH Activates all four functional melanocortin receptors (MC1R, MC3R, MC4R, MC5R) In vivo: visible pigmentation of lizard skin within hours, not days as with -MSH Why it matters: This is the foundational publication of Melanotan II
Second, the FDA explicitly named HIMS, which is virtually unprecedented in a Commissioner-level statement
The recommended CJC-1295 Ipamorelin dosage ranges from 100-300 mcg of each peptide daily, administered via subcutaneous injection before bed for optimal growth hormone release
